Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year

2026-02-23 13:49:01 ET

On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.

According to a recent SEC filing , Baker Bros. Advisors increased its stake in Praxis Precision Medicines by 437,000 shares during the fourth quarter of 2025. The estimated value of the transaction is $81.38 million, calculated using the period's average closing price. The post-trade stake stood at 1,126,488 shares, with the quarter-end valuation up by $295.48 million due to both trading activity and price movements.

Praxis Precision Medicines is a Boston-based biotechnology company focused on advancing therapies for neurological and psychiatric disorders with significant unmet medical need. The company leverages a robust pipeline of differentiated clinical candidates targeting neuronal imbalance, supported by strategic collaborations and licensing agreements. Its approach aims to deliver first-in-class or best-in-class treatments, positioning Praxis as a potential leader in the CNS therapeutics market.

Continue reading